Veeva Vault Quality Helps Neuraxpharm Drive Seamless Quality Processes And Collaborate With Over 100 CDMOs
Leading specialty pharmaceutical manufacturer improves compliance, oversight and inspection readiness with Veeva Vault QualityDocs and Veeva Vault Training
Barcelona /PRNewswire/ - Veeva Systems (NYSE: VEEV ) today announced that Neuraxpharm will use Veeva Vault QualityDocs and Veeva Vault Training to improve its quality processes. Veeva's quality applications will help Neuraxpharm achieve better monitoring and inspection readiness while improving collaboration across its network of over 100 contract development and manufacturing organizations (CDMOs).
"Veeva Vault Quality enables Neuraxpharm to consolidate GxP documentation and quality training on one platform, making quality operations more efficient and scalable," says Susanne Cater , Head of Corporate Quality at Neuraxpharm. "Veeva Vault QualityDocs and Veeva Vault Training enable us to improve quality document management and compliance, including collaboration with CDMOs."
Neuraxpharm is a leader in the field of central nervous system (CNS) diseases. Vault QualityDocs supports the efficient management of GxP content and information sharing between sites, while Vault Training enables Neuraxpharm to deliver training and curricula to ensure GxP compliance.
"Veeva Vault Quality enables Neuraxpharm to streamline content and training so the company can scale as it expands its product portfolio," said Sofia Lange , Director of Quality Strategy for Europe at Veeva. "We are excited to partner with Neuraxpharm to improve quality across the organization and maintain production of vital CNS treatments for patients."
Learn more
For more information about Veeva Vault Quality, visit: veeva.com/eu/VaultQuality
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product quality, and customer success, Veeva serves more than 1,000 customers, from the world's largest biopharmaceutical companies to emerging biotech companies. As a public benefit corporation, Veeva strives to align the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com/eu .
Veeva Forward-Looking Statements
This press release contains forward-looking statements about Veeva's products and services and the expected results or benefits from using our products and services. These statements are based on our current expectations. Actual results may differ materially from those set forth in this press release, and we undertake no obligation to update such statements. There are numerous risks that could adversely affect our results, including the risks and uncertainties disclosed in our Form 10-Q for the period ended April 30, 2024 , which can be found here (see pages 35 and 36 for a summary of risks that may affect our business), and in our subsequent SEC filings, which can be found at sec.gov .
Source: Veeva Systems
Copyright 2024 PR Newswire. All Rights Reserved